New combo therapy targets genetic breast cancers before surgery
NCT ID NCT04584255
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This study tests two drugs, niraparib and dostarlimab, given before surgery to people with BRCA or PALB2 gene mutations and early-stage breast cancer. The goal is to see if the treatment shrinks tumors and boosts immune activity. 62 participants are enrolled, and the study is active but no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
University of Washington / Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Yale University Cancer Center
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.